Introduction
============

Coronary artery disease (CAD) is the single most frequent cause of death worldwide; nearly 7.4 million individuals succumb to CAD every year, accounting for 13.1% of all deaths ([@b1-etm-0-0-3211]). Furthermore, in patients with CAD, acute myocardial infarction (AMI) is the twelfth leading cause of cardiac death ([@b2-etm-0-0-3211]). Each year, \>3 and 4 million individuals suffer from ST-elevated myocardial infarction (STEMI) and non-ST-elevated myocardial infarction (NSTEMI), respectively ([@b3-etm-0-0-3211]). China is the largest of the 16 developing countries, with a rapidly developing economy; in China, ≥500,000 individuals have AMI out of a total of 2 million cardiovascular disease cases annually ([@b4-etm-0-0-3211]). According to research conducted by Hopkin University, \~45% of the adult population has ≥1 chronic disease; this proportion increases to 90% in individuals \>65 years of age, who represent more than half of patients with myocardial infarction ([@b5-etm-0-0-3211],[@b6-etm-0-0-3211]). Unfortunately, following AMI, neurohormonal systems that promote pathological ventricular remodeling and progressive myocardial damage are activated ([@b7-etm-0-0-3211]); patients consequently develop HF due to an impairment of left ventricular myocardial function ([@b8-etm-0-0-3211]), which is associated with high morbidity and mortality. The appropriate management of AMI, including pharmacology, thrombolysis and invasive therapy, may marginally decrease vascular complications, composite bleeding complications and mortality ([@b9-etm-0-0-3211]). However, treatment strategy varies with age, gender, ethnicity, clinical circumstance and socioeconomic status. In addition, ethnic differences in etiology, outcome and response to therapy in patients with HF and discrepancies in clinical practice require validation ([@b10-etm-0-0-3211],[@b11-etm-0-0-3211]). Numerous studies have been conducted on HF rates and the beneficial clinical effects of evidence-based drug therapy have been demonstrated in western countries ([@b12-etm-0-0-3211],[@b13-etm-0-0-3211]). Chongqing is the biggest industrial and commercial center in southwest China and is diverse in ethnicity, living standards and population ([@b14-etm-0-0-3211]). However, little is known with regards to the characteristics, prognosis of HF following AMI and HF medications in patients from China and other Asian countries in clinical practice. The present study aimed to compare the baseline clinical profile, clinical treatment in clinical practice, cardiovascular events and in-hospital mortality rates of AMI patients with and without HF in southwestern China.

Materials and methods
=====================

### Ethics statement

The present investigation was approved by the ethics committee of the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). Informed consent was not obtained since this was a retrospective study and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki. The patients\' information was anonymized and de-identified when the data were collected and analyzed.

### Study design and population

Patients who were hospitalized in the First Affiliated Hospital of Chongqing Medical University due to AMI (including STEMI and NSTEMI) between February 2009 and December 2012 were recruited. Patients \<18 years old, those who suffered from stable or unstable angina instead of myocardial infarction and those with a history of HF, congenital heart diseases, valvular heart diseases, cardiomyopathy, viral myocarditis, sarcoidosis, or severe arrhythmias were excluded from the study. A total of 591 patients were included in the investigation and identified according to the HF status and the type of AMI.

Data were collected retrospectively from hospital records, including clinical characteristics, initial evaluations, therapeutic management, major cardiovascular events (MACEs) and in-hospital mortality and were compared between the two groups of AMI patients. The use of the evidence-based drugs, including angiotensin converting enzyme inhibitors (ACEIs) and β-blockers (BBs), in AMI patients with HF in clinical practice during hospitalization was further analyzed. Accordingly, patients were divided into two groups: Patients receiving co-treatment with BBs and ACEIs and patients either receiving no treatment or treated with BBs or ACEIs alone.

### Diagnostic criteria

All 591 patients suffered from AMI on at least one occasion. AMI patients with HF during hospitalization was defined as: i) Simultaneous presentation of AMI and HF; or ii) development of HF during hospitalization for AMI in a patient with no previous history of HF due to other diseases.

According to the European Society of Cardiology, the American College of Cardiology Foundation, the American Heart Association and the World Heart Federation universal definition of AMI (2012) ([@b15-etm-0-0-3211]) and a previous study ([@b16-etm-0-0-3211]), the diagnosis of STEMI was defined by the following criteria: i) Chest pain lasting for ≥30 min that could not be completely relieved by nitrates; ii) new ST segment elevation present at the J point in two or more contiguous leads; iii) increase in serum levels of creatine kinase, creatine kinase MB (CKMB) fraction, or troponins to more than twice the upper limit of normal levels; and/or iv) evidence of diseased vessels as determined by cardiac angiography. A diagnosis of NSTEMI was accepted in the absence of ST-segment elevation, the presence of ischemic ST-segment or T-wave changes for ≥24 h with positive cardiac enzymes and/or a typical clinical presentation. Chronic obstructive pulmonary disease (COPD) was diagnosed by physicians according to patient clinical respiratory symptoms (dyspnea, cough and/or sputum production), laboratory test results (including blood gas analysis and oxygen saturation) and case histories.

The diagnosis of HF in the present study was based on the following conditions, which were predominantly established from the European Society of Cardiology guideline for AMI-associated HF ([@b17-etm-0-0-3211]): i) Onset of cardinal manifestations of HF (such as dyspnea and fatigue); ii) rales in more than one-third of the lung field (Killip class II or higher); iii) pulmonary edema or congestion on chest radiography, with no indication of a non-cardiac cause; and/or iv) varying degrees of abnormal brain natriuretic peptide or N-terminal pro β-type natriuretic peptide levels. MACEs included atrial fibrillation, ventricular arrhythmia, major bleeding, cardiogenic shock, recurrent ischemia and recurrent myocardial infarction.

Cardiogenic shock was defined as systolic blood pressure \<80 mmHg in the absence of hypovolemia and associated with cyanosis, cold extremities, changes in mental status and persistent oliguria ([@b18-etm-0-0-3211]). Bleeding complications were assessed by the Thrombolysis In Myocardial Infarction criteria and were classified as major bleeding (intracranial, overt bleeding with a \>50 g/l reduction in hemoglobin levels, or hematocrit \>15%) or minor bleeding (spontaneous gross hematuria or hematemesis with a \>30 g/l reduction in hemoglobin levels and a \<15% reduction in hematocrit) ([@b19-etm-0-0-3211]).

### Statistical analyses

Clinical characteristic data were analyzed using χ^2^ tests for discrete variables and two-tailed Student\'s t-tests for continuous variables and were presented as the number (frequency) and mean ± standard deviation, respectively. Non-normal continuous variables were analyzed using a Mann-Whitney U-test and were presented as the median and range. In addition, logistic regression analysis was performed using a backward selection model in the following order: i) Presence of post-AMI HF; ii) risk factors such as age, gender, heart rate, smoking, drinking, diabetes, hypertension, COPD, history of angina, prior stroke, chronic renal failure, hyperlipidemia, family history of coronary artery disease, history of myocardial infarction, STEMI/NSTEMI myocardial infarction type at presentation, hospitalization, left ventricular ejection fraction (LVEF), CKMB and length of hospital stay; iii) in-hospital events, including atrial fibrillation and ventricular arrhythmia, re-ischemia, major bleeding, re-infarction and cardiogenic shock; iv) medications during hospitalization, including antiarrhythmic, oral BBs, calcium-channel blockers, ACEIs or angiotensin receptor blockers, aspirin and heparin; and v) cardiac angiography and primary reperfusion strategies, including thrombolysis and percutaneous coronary intervention (PCI). As numerous variables were entered into the logistic regression model, tests for multicollinearity between variables were performed. A covariance matrix did not demonstrate significant multicollinearity and tolerance values of all variables in a linear regression model were high, indicating low multicollinearity.

Due to the limited follow-up period in this study, the entire length of hospital stay tended to correlate with several risk factors and in-hospital mortality. The in-hospital survival curve was calculated using the Kaplan-Meier method and a log-rank test ([Figs. 1](#f1-etm-0-0-3211){ref-type="fig"}--[3](#f3-etm-0-0-3211){ref-type="fig"}) and χ^2^ test ([Fig. 4](#f4-etm-0-0-3211){ref-type="fig"}) were used to compare groups. Statistical analyses were performed using SPSS software version 18.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant result for all tests.

Results
=======

### Baseline characteristics

The overall demographic and baseline characteristics of patients with or without first and new-onset HF following STEMI or NSTEMI are shown in [Table I](#tI-etm-0-0-3211){ref-type="table"}. Among the 412 STEMI and 179 NSTEMI patients, 162 (38.3%) and 60 (33.5%), respectively, developed first and new-onset HF during hospitalization. Patients with both STEMI and NSTEMI who developed in-hospital HF were significantly older and had a higher rate of renal failure (P\<0.05). In addition, these patients had a higher heart rate, lower LVEF and a higher rate of arrhythmia on admission (P\<0.05), and the rate of atrial fibrillation on admission was significantly higher in NSTEMI patients with HF (P\<0.001). The rate of ventricular arrhythmia did not differ significantly in either STEMI and NSTEMI patients according to HF. A preserved LVEF (≥51%) was noted in 63.6% of STEMI patients and in 63.3% of NSTEMI patients who developed HF following hospitalization. However, STEMI patients with HF were more likely to have a history of COPD and a longer delay prior to hospital presentation (P\<0.05). Accordingly, the peak CKMB value for STEMI patients with in-hospital HF was significantly higher compared with that for STEMI patients without HF and the peak serum creatinine and urea nitrogen values were also higher in HF patients with both AMI types. A further analysis of post-AMI HF in patients with STEMI showed that 57.4% of patients had Killip class II AMI, 17.9% had Killip class III AMI and 21.6% had Killip class IV AMI. Among the patients with NSTEMI, 70% had Killip class II AMI, 16.7% had Killip class III AMI and 13.3% had Killip class IV AMI.

### Medical treatment

The medications prescribed to patients with AMI during hospitalization are listed in [Table II](#tII-etm-0-0-3211){ref-type="table"}. Antiarrhythmic agents and HF medication (such as diuretics and digitalis) were more often prescribed to post-AMI (both STEMI and NSTEMI) HF patients. Due to contraindications (including hemorrhagic disease and stomach disease) and incomplete original medication administration records in certain cases, aspirin was prescribed and thus some data bias may exist. According to standard medical norms, all patients diagnosed with AMI should receive aspirin treatment except in cases of severe contraindications. There were no clinically significant differences in the development of post-AMI HF following the use of aspirin, BBs and ACEIs, which serve a crucial function in the prevention of cardiac remodeling and in the treatment of simultaneous HF and AMI. Therefore, the use of BBs and ACEIs in patients with or without HF was further analyzed and the results are shown in [Table III](#tIII-etm-0-0-3211){ref-type="table"}. Patients with HF during hospitalization treated with both classes of medication (n=142) had a significantly higher survival rate compared with untreated patients or those treated with either class of medication alone (n=80; 94.4 vs. 67.5%; P\<0.001), although the two subgroups had similar baseline characteristics. Patients with HF receiving neither BBs nor ACEIs had the lowest survival rate ([Table III](#tIII-etm-0-0-3211){ref-type="table"}). However, AMI patients with HF that received both classes of recommended medication had a significantly lower survival rate compared with AMI patients without HF (P\<0.001; [Fig. 1](#f1-etm-0-0-3211){ref-type="fig"}).

Notably, post-AMI patients with HF were less likely to undergo cardiac angiography and PCI compared with patients without HF (P\<0.05; [Table II](#tII-etm-0-0-3211){ref-type="table"}). Although there were no significant differences in culprit vessels and vessel disease, as in the case of patients with NSTEMI, patients with STEMI that developed in-hospital HF had severe right coronary stenosis, left circumflex disease, or three vessel disease.

### Clinical outcomes

As shown in [Table IV](#tIV-etm-0-0-3211){ref-type="table"} and [Fig. 2](#f2-etm-0-0-3211){ref-type="fig"}, the in-hospital mortality rate was significantly higher in STEMI (15.4 vs. 3.3%) and NSTEMI (15 vs. 0.8%) patients with HF (P\<0.001) compared with those without HF, as was the length of hospital stay. Non-fatal in-hospital outcomes such as atrial fibrillation and ventricular arrhythmia were significantly more frequent in post-AMI patients with HF (P=0.001 and P\<0.001, respectively); however, there were no significant differences in the rates of recurrent ischemia, major bleeding, re-infarction or high-grade atrioventricular blockage between HF and non-HF patients. The prevalence of MACEs was higher in HF patients with either type of AMI; post-AMI HF patients with MACEs had a higher risk of in-hospital mortality compared with those without MACEs (P\<0.001; [Table IV](#tIV-etm-0-0-3211){ref-type="table"}; [Fig. 3](#f3-etm-0-0-3211){ref-type="fig"}).

### Predictors of outcome

The logistic regression analysis performed to assess the effect of HF while adjusting for potential confounding factors is shown in [Table V](#tV-etm-0-0-3211){ref-type="table"}. Cardiogenic shock \[odds ratio (OR), 8.21; 95% confidence interval (CI), 2.75--24.48; P\<0.001\] following AMI was the strongest predictor of in-hospital mortality, in addition to the onset of HF (OR, 2.88; 95% CI, 1.00--8.28; P=0.049) and age (OR, 1.07; 95% CI, 1.02--1.12; P=0.006). Similarly, in-hospital mortality rates were over two times higher in patients with Killip class III and IV AMI compared with patients with Killip class I and II AMI ([Fig. 4](#f4-etm-0-0-3211){ref-type="fig"}), indicating that Killip class was associated with in-hospital mortality. Conversely, treatment with oral BBs (OR, 0.43; 95% CI, 0.61--0.92; P=0.045), treatment with ACEIs (OR, 0.41; 95% CI, 0.49--0.87; P=0.041), the CKMB value (OR, 1.003; 95% CI, 1.00--1.01; P=0.038) and length of hospital stay (OR, 0.93; 95% CI, 0.87--0.99; P=0.034) were inversely correlated with in-hospital mortality. Co-treatment with BBs and ACEIs was associated with reduced mortality (OR, 0.24; 95% CI, 0.16--0.37; P\<0.001). Notably, a history of COPD was inversely associated with in-hospital mortality (OR, 0.05; 95% CI, 0.00--0.67; P=0.023). The performance of cardiac angiography (OR, 0.12; 95% CI, 0.04--0.35; P\<0.001) was associated with decreased in-hospital mortality. The logistic regression model demonstrated that patients with COPD in the overall AMI population had a reverse relationship with in-hospital mortality. Patients with AMI who presented with COPD were more likely to develop HF and have a higher prescription rate of diuretics and digitalis (P\<0.05), but a reduced use of BBs (P\<0.001; [Table VI](#tVI-etm-0-0-3211){ref-type="table"}).

Discussion
==========

The present study demonstrated that AMI patients with HF were at a higher risk of adverse in-hospital outcomes and had a higher incidence of MACEs compared with AMI patients without HF. In particular, in-hospital mortality was close to five-fold higher in STEMI patients with HF, as compared with that of patients without HF and even higher in NSTEMI patients with HF (15.0 vs. 0.8%). Cardiogenic shock and HF during hospitalization were strong predictors of in-hospital mortality. Medications such as BBs or ACEIs were insufficiently prescribed, although the prescription rate was higher compared with that indicated by previous studies ([@b20-etm-0-0-3211],[@b21-etm-0-0-3211]). AMI patients with HF who received neither class of recommended medications (BBs or ACEIs) had a significantly higher risk of in-hospital mortality compared with those treated with the recommended medications. In addition, they were less likely to be examined by cardiac angiography and were treated with reperfusion therapy.

In the present study, HF occurred in 38.3% of patients with STEMI and in 33.5% of patients with NSTEMI. This incidence was similar to rates reported in western countries (32.4 and 34%, respectively) ([@b22-etm-0-0-3211],[@b23-etm-0-0-3211]), although the Killip class in the present study was higher compared with that reported in an earlier study ([@b24-etm-0-0-3211]). One possible reason for the higher Killip class may be a longer pre-hospital delay compared with studies conducted in western countries (mean time, \<6 h) and a longer delay in revascularization ([@b25-etm-0-0-3211]). A previous study demonstrated that a shorter door-to-balloon time was associated with a decline in the incidence of cardiovascular events and therefore, improved outcome following AMI ([@b26-etm-0-0-3211]). Furthermore, not all patients underwent immediate cardiac angiography or were taken directly to a PCI-capable center (hospitals with doctors able and qualified to perform PCI). These results were concordant with those of a previous study, in which \~50% of the patients with AMI were transferred to PCI-capable centers from an interim hospital without PCI capabilities ([@b27-etm-0-0-3211]). Pre-hospital system delays vary and are correlated with geographical and local factors such as urbanization and the availability of emergency medical services ([@b28-etm-0-0-3211]). Regardless of location (western countries or China), the time to reperfusion therapy for patients with STEMI transferred for primary PCI is often prolonged, with the guideline-recommended overall time of \<90 min being achieved in only a minority of transferred patients ([@b29-etm-0-0-3211]). Considering the geography and traffic situation of southwestern China, the mean pre-hospital delay is unable to reach the guideline-recommended goals ([@b30-etm-0-0-3211]). The direct association between total ischemic time and severity of myocardial injury and mortality has been well-established for patients with STEMI ([@b31-etm-0-0-3211]). These results suggest that all efforts should be aimed at reducing total ischemic time to achieve improved prognosis and life expectancy.

As patients with HF are generally older and have co-morbidities, physicians may hesitate to recommend cardiac medications or procedures despite an advantageous risk-to-benefit ratio due to concerns regarding adverse effects ([@b32-etm-0-0-3211]). Cardiovascular drugs frequently prescribed to patients with HF were more frequently administered, except for BBs, ACEIs and aspirin. Although the utilization rate of BBs and ACEIs remained lower in patients with HF compared with AMI patients without HF during each period under study, the use of these two medications increased progressively for HF through the early 1990s ([@b33-etm-0-0-3211],[@b34-etm-0-0-3211]). However, the issue of a persistent gap between ideal practice and the actual use of ACEIs for HF cannot be ignored. It is difficult to close this gap in the adequate use of evidence-based medications due to numerous clinical conditions or complex natural and human factors (including co-morbid illnesses, economics, geography, ethnic or racial differences and genetic factors) ([@b10-etm-0-0-3211],[@b11-etm-0-0-3211]). Notably, the present analysis demonstrated that patients with the poorest cardiac function benefited as much as patients with better function. Data from the United States indicates that the percentage of patients receiving ACEIs or angiotensin-receptor blockers is \<80% ([@b35-etm-0-0-3211]), whereas in western Australia, the prescription rate is 71% ([@b36-etm-0-0-3211]). Differences in ethnicity have been reported among these patients with HF with preserved systolic function (the BB prescription rate is 80% in Caucasians, 13.4% in African Americans, 1.0% in Asians and 0.4% in Native Americans). Another study demonstrated that African Americans with hypertension do not respond as well as Caucasians to treatment with BB, which may be due to differences in the sympathetic nervous system or in the use of drugs ([@b37-etm-0-0-3211],[@b38-etm-0-0-3211]). According to East Asian studies, patients with HF had a better utilization rate of ACEIs (70--90%) and BBs (60--70%) ([@b12-etm-0-0-3211],[@b39-etm-0-0-3211]), which may partly explain the lower mortality rate (2.3%, 6.6%). Patients treated with ACEIs and BBs had a lower all-cause mortality rate, lower cardiovascular mortality rate and higher long-term survival rate ([@b33-etm-0-0-3211],[@b36-etm-0-0-3211],[@b40-etm-0-0-3211]). In certain metropolitan regions of China, the utilization rates of ACEIs and BBs were \~70 and 50% among patients with HF, respectively ([@b41-etm-0-0-3211],[@b42-etm-0-0-3211]), whereas the utilization rate of BBs was \<40% in general hospitals ([@b43-etm-0-0-3211]) and lower in rural areas. The prescription rates of ACEIs (42.8--68.4%) ([@b22-etm-0-0-3211],[@b44-etm-0-0-3211]) and BBs (37.7--77%) ([@b36-etm-0-0-3211],[@b45-etm-0-0-3211]) in previous studies in other countries were lower compared with those reported in the present study (ACEIs, 71.6% and BBs, 74.7--90%), which may partly explain the higher short-term mortality rates in the previous studies (15.9--17.7%) compared with those of the present study (15--15.4%). Furthermore, the MONICA plan (Sino-MONICA project) reported that the annual morbidity and mortality of Chinese patients with cardiovascular disease are below worldwide rates and similar rates were observed in Japan, Korea and other Asian countries ([@b46-etm-0-0-3211]). As the first-line therapy for AMI with HF according to the European Society of Cardiology guidelines for the diagnosis and treatment of HF ([@b47-etm-0-0-3211]), treatment with ACEIs should be administered in all patients with preserved ejection fraction as rapidly as possible following HF diagnosis and maintained during the various stages, unless there is a contraindication. Oral BBs should be initiated in the first 24 h in patients with STEMI without severe contraindications. Following logistic regression, treatment with BBs or ACEIs had a beneficial effect against in-hospital mortality, whereas calcium-channel blockers did not affect in-hospital mortality ([@b48-etm-0-0-3211],[@b49-etm-0-0-3211]). Meta-analyses of the use of ACEIs in patients with AMI and left ventricular systolic dysfunction showed a significant reduction in cardiovascular events and mortality with ACEI use. International recommendations emphasize the protective role of BBs in patients with both AMI and HF ([@b50-etm-0-0-3211],[@b51-etm-0-0-3211]). However, further efforts are required to reduce the gap between ideal practice and the actual use of recommended medications in China due to a deficient medical system and an underdeveloped medical information system, in a country with cultural and demographic similarities and geographical and social and physical environmental differences ([@b52-etm-0-0-3211]). China is currently undergoing rapid socioeconomic changes further to economic reforms, particularly, increases in the gross national product, average income and personal expenditure have been reported ([@b46-etm-0-0-3211]). Further studies are required in order to investigate the differences between Asia and the rest of the world and to identify the most effective ways to improve the utilization rate of recommended medications that have recently become more available.

In line with the results of previous studies, the present study demonstrated that AMI patients with HF were less likely to undergo primary PCI than non-HF patients ([@b22-etm-0-0-3211],[@b23-etm-0-0-3211]). Early revascularization has been shown to decrease infarct size, improve cardiac function and decrease the rate of cardiogenic shock. Although studies have reported the survival benefit of thrombolysis and PCI in patients with HF ([@b53-etm-0-0-3211]), other studies including the present one have not ([@b54-etm-0-0-3211]). Thrombolysis and PCI are negatively associated with in-hospital mortality in patients with HF, which may be explained by prolonged pre-hospital delay, lower reperfusion rates, associated mechanical complications (such as mitral regurgitation) or complete infarction. The limited sample size, short-term follow-up and unavoidable sample bias in the present study may have masked the positive effects of the revascularization strategy. According to the 2013 American College of Cardiology Foundation/American Heart Association guidelines for MI, primary PCI is the recommended method of reperfusion when it can be performed in a timely manner (≤90 min) by experienced operators. However, if thrombolysis therapy is indicated or selected as the primary reperfusion strategy, it should be administered within 30 min of hospital arrival ([@b30-etm-0-0-3211]). Similar to the results of previous studies ([@b54-etm-0-0-3211],[@b55-etm-0-0-3211]), cardiac angiography had a positive effect on in-hospital mortality, likely due to the fact that cardiac angiography can be used to grade the complexity and extent of AMI and patients can receive relevant therapy accordingly in a timely and appropriate manner. In addition, cardiac angiography can be used to assess the requirement for revascularization therapy for lesions, the number of diseased coronary arteries and the location and calcification of the vessels that determine AMI complexity ([@b54-etm-0-0-3211]). However, further investigation is required to clarify whether primary PCI is superior to thrombolysis therapy for AMI patients with HF.

In the present study, the in-hospital mortality rate was 15--15.4% in the HF group, in the mid-range of previously reported in-hospital mortality rates in western countries (21.6%) ([@b22-etm-0-0-3211]) and China (12.3%) ([@b56-etm-0-0-3211]). Certain hospital-based studies in China have reported short-term mortality rates following AMI ranging from 8.1--13.1% ([@b41-etm-0-0-3211],[@b57-etm-0-0-3211]), which was higher compared with that in South Asian and Caucasian patients. This may be partly explained by a delayed presentation to emergency departments from the onset of AMI symptoms ([@b58-etm-0-0-3211]). Considering the large and complex population in China, health education in cardiovascular patients as well as in healthy individuals is lacking, resulting in lack of attention in acute severe cases. In contrast to numerous studies ([@b59-etm-0-0-3211],[@b60-etm-0-0-3211]), the logistic regression model of the present study for the overall AMI population demonstrated that COPD was inversely correlated with in-hospital mortality. AMI patients with COPD were more likely to develop HF and had higher prescription rates of diuretics and digitalis (P\<0.05), but a lower BB prescription rate (P=0.002). It is plausible that in these patients with COPD, the alterations in inflammation, endothelial function and associated platelet reactivity may have destabilized the underlying coronary disease. As a result of inflammation, patients with COPD had a decreased platelet volume and an increased platelet count ([@b61-etm-0-0-3211]). Marked platelet inhibition may reduce cardiac adverse events in patients with COPD; however, this hypothesis requires validation ([@b62-etm-0-0-3211]). Another explanation may be that COPD patients suffered from chronic hypoxia, which is responsible for hemodynamic changes and the activation of the rennin-angiotensin system. Therefore, these patients with COPD may have a strong tolerance against the pathological changes of MI or HF; further studies are required to clarify the underlying mechanisms. The present cross-sectional study only assessed prognosis in terms of length of hospital stay (in-hospital mortality), which limited a long-term follow-up to determine whether the short-term and long-term prognoses of AMI patients with COPD differ. The Sino-MONICA project demonstrated that in China, cardiovascular disease mortality and risk factor levels were higher in the north and lower in the south ([@b63-etm-0-0-3211]). Similar to previous findings, a higher Killip class was associated with increased hospital mortality, and therefore the Killip classification serves as an accurate tool for early risk assessment of in-hospital mortality in patients with AMI ([@b64-etm-0-0-3211]). Although the incidence and survival rates of patients with HF have improved in the last decade ([@b13-etm-0-0-3211]), the association between a higher Killip class and worse prognosis has not changed.

Several limitations and strengths are noteworthy in the present study. Firstly, in an HF setting with a short hospital stay, medications could not reach the recommended level of titration. Secondly, patients with HF could not undergo cardiac angiography and rapidly receive sufficient therapy due to their poor condition. However, this study has notable strengths as well. Data from the hospital are real-case observations and were collected consecutively. With these representative data, the present investigation demonstrated how AMI was managed in daily clinical practice in southwestern China and thus demonstrate how it may be improved.

The present results demonstrated that AMI patients with HF have a higher mortality rate and are at greater risk of hospital-associated adverse outcomes compared with AMI patients without HF in Southwestern China. Guideline-recommended medications and invasive testing are used less frequently in these patients. In China, the persistent gap between ideal practice and actual use of ACEIs and BBs for HF cannot be ignored. The performance of precise diagnostic methods such as cardiac angiography and timely administration of standard recommended medications were associated with improved in-hospital mortality.
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###### 

Principle characteristics of the study population evaluated according to HF and AMI status.

                                                                          STEMI (412 individuals)                          NSTEMI (179 individuals)                                         
  ----------------------------------------------------------------------- ------------------------- ---------------------- -------------------------- ------------------ ------------------ ---------
  Mean age (years)                                                        70.7±10.4                 61.7±11.2                \<0.001                  74.0±9.9           66.5±11.9          \<0.001
  Men                                                                       82 (50.6)               139 (55.6)             0.36                       33 (55.0)          61 (51.3)            0.750
  Heart beats/min)                                                        85.5±24.6                 76.4±17.0                \<0.001                  85.7±21.9          75.9±15.9            0.001
  Diabetes mellitus                                                         34 (21.0)                 59 (23.6)              0.55                     24 (40.0)          31 (26.1)            0.060
  Hypertension                                                              81 (50.0)               118 (47.2)               0.61                     36 (60.0)          73 (61.3)            0.870
  Smoking                                                                   64 (39.5)               151 (60.4)               \<0.001                  20 (33.3)          49 (41.2)            0.330
  Drinking                                                                  45 (27.8)               100 (40.0)               0.01                     15 (25.0)          31 (26.1)            1.000
  COPD                                                                      23 (14.2)                 8 (3.2)                \<0.001                    8 (13.3)         11 (9.2)             0.440
  Previous angina                                                           47 (29.0)                 92 (36.8)              0.11                     21 (35.0)          51 (42.9)            0.340
  Previous MI                                                             12 (7.4)                  16 (6.4)                 0.69                       7 (11.7)         4 (3.4)              0.050
  Stroke                                                                    5 (3.1)                   7 (2.8)                1.00                     5 (8.3)            8 (6.7)              0.760
  Chronic renal failure                                                   10 (6.2)                    3 (1.2)                0.007                      9 (15.0)         4 (3.4)              0.010
  Hyperlipidemia                                                          33 (2.4)                    60 (24.0)              0.40                     14 (23.3)          32 (26.9)            0.720
  Family CAD                                                              10 (6.2)                    26 (10.4)            0.16                       4 (6.7)            15 (12.6)            0.310
  Killip class                                                                                                                                                                              
    II                                                                    93 (57.4)                 --                     42 (70.0)                  --                                    
    III                                                                   29 (17.9)                 --                     10 (16.7)                  --                                    
    IV                                                                    35 (21.6)                 --                     8 (13.3)                   --                                    
  Arrhythmia                                                                20 (12.3)                 8 (3.2)              \<0.001                    10 (16.7)          9 (7.6)              0.070
    AF                                                                    16 (9.9)                    4 (1.6)              0.11                         7 (11.7)         5 (4.2)            \<0.001
    VA                                                                      4 (2.4)                   4 (1.6)              0.69                       3 (5.0)            4 (3.4)              0.720
  Heart blockage^[a](#tfn1-etm-0-0-3211){ref-type="table-fn"}^              23 (14.2)                 26 (10.4)            0.28                         8 (13.3)         13 (10.9)            0.630
  Prehospital delay (h)                                                   15.1±9.6                  12.4±9.5                 0.006                    18.8±8.1           17.0±8.9             0.180
  LVEF                                                                                                                     \<0.001                                                          \<0.001
    ≤40%                                                                  13 (8.0)                    4 (1.6)                                           6 (10.0)         4 (3.4)            
    41\~50%                                                                 46 (28.4)                 43 (17.2)                                       16 (26.7)          7 (5.9)            
    ≥51                                                                   103 (63.6)                203 (81.2)                                        38 (63.3)          108 (88.2)         
  Serum creatinine (µmol/l)                                               109.6±86.4                80.4±22.2              \<0.001                    132.4±116.6        85.6±36.5          \<0.001
  Urea nitrogen (mmol/l)                                                    8.0±4.8                 6.7±6.2                  0.017                    9.8±4.9            6.7±6.8              0.002
  CKMB^[b](#tfn2-etm-0-0-3211){ref-type="table-fn"}^ (ng/ml) and median     29.45 (0.7--500.0)        21.00 (0.4--515.0)   0.04                       7.7 (0.1--500.0)   9.3 (0.1--382.8)     0.850

Heart blockage including first-, second-, and third-degree heart blockage.

Examined using the Mann-Whitney U-test. Numbers in parentheses are percentages and continuous variables are presented as means ± standard deviation. HF, heart failure; AF, atrial fibrillation; AMI, acute myocardial infarction; CAD, coronary artery disease; CKMB, creatine kinase MB; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; VA, ventricular arrhythmias.

###### 

Medical treatment during hospitalization (n=591).

                                                                              STEMI                         NSTEMI                                  
  --------------------------------------------------------------------------- ------------- --------------- --------- -------------- -------------- ---------
  Treatment                                                                                                                                         
    Antiarrhythmic agents                                                       28 (17.3)   23 (9.2)          0.020   13 (21.7)        3 (2.5)      \<0.001
    β-blockers                                                                121 (74.7)    204 (81.6)        0.110   54 (90.0)      101 (84.9)       0.490
    CCB                                                                         38 (23.5)     53 (21.2)       0.630   19 (31.7)        38 (31.9)      1.000
    ACEI/ARB                                                                  116 (71.6)    188 (75.2)        0.420   43 (71.7)        92 (77.3)      0.460
    Diuretics                                                                 126 (77.8)      37(14.8)      \<0.001   53 (88.3)        15 (12.6)    \<0.001
    Digitalis                                                                   40 (24.7)     4 (1.6)       \<0.001     9 (15.0)       4 (3.4)        0.010
    Statin                                                                    146 (90.1)    240 (96.0)        0.020   51 (85.0)      117 (98.3)       0.001
    Aspirin                                                                   147 (90.7)    233 (93.2)        0.450   46 (76.7)      108 (90.8)       0.020
    Heparin^[a](#tfn3-etm-0-0-3211){ref-type="table-fn"}^                     126 (77.8)    194 (77.6)        1.000   40 (66.7)        93 (78.2)      0.110
    Clopidogrel                                                               156 (96.3)    246 (98.4)        0.200   57 (95.0)      115 (96.7)       0.690
    Thrombolytic therapy                                                        22 (13.6)     30 (12.0)       0.650   1 (1.7)          3 (2.5)        1.000
  Intervention                                                                                                                                      
    Cardiac angiography                                                         99 (61.1)   188 (75.2)        0.003   26 (43.3)        83 (69.7)      0.001
    PCI                                                                         78 (48.1)   167 (66.8)      \<0.001   18 (30.0)        65 (54.6)      0.002
  TIMI flow grade at PCI 2--3                                                   75 (96.2)     167 (100.0)   --          18 (100.0)     65 (100.0)   --
  Numbers of diseased vessels^[c](#tfn5-etm-0-0-3211){ref-type="table-fn"}^   99            188               0.170   26             83               0.500
    One                                                                         22 (22.2)     59 (31.4)     --          4 (15.4)       29 (34.9)    --
    Two                                                                         26 (26.3)     52 (27.7)     --          3 (11.5)       16 (19.3)    --
    Three                                                                       51 (51.5)     77 (40.9)     --        19 (73.1)        38 (45.8)    --
  Culprit artery^[b](#tfn4-etm-0-0-3211){ref-type="table-fn"}^                                                        0.23                            0.350
  Left anterior descending                                                      81 (50.0)   141 (56.4)      --        29 (48.3)        62 (52.1)    --
    Right coronary                                                              63 (38.9)     87 (34.8)     --        15 (25.0)        23 (19.3)    --
    Circumflex                                                                16 (9.9)      15 (6.0)        --        0                5 (4.2)      --
    Not localized                                                             2 (1.2)         7 (2.8)       --        16 (26.7)        29 (24.4)    --

Including intravenous and subcutaneous heparin

The diagnosis of culprit artery was conducted according to the results of percutaneous coronary intervention and electrocardiogram.

Numbers of vessels disease were analyzed according to patients who underwent cardiac angiography. Figures in parentheses are percentages. ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CCB, calcium channel blockers; HF, heart failure; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

###### 

Comparison of post-AMI patients with HF with or without BB and ACEI treatment.

  Variable                                                                                 HF patients with both BB + ACEI (n=142)   Untreated HF patients or treated with either class of drug (n=80)   P-value
  ---------------------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------- ---------
  Mean age (years)                                                                         71.5±10.7                                 71.7±9.8                                                              0.940
  Men                                                                                        74 (52.1)                                 41 (51.3)                                                           1.000
  Diabetes mellitus                                                                          43 (30.3)                                 15 (18.8)                                                           0.080
  Hypertension                                                                               74 (52.1)                                 42 (52.5)                                                           1.000
  COPD                                                                                       16 (11.3)                                 15 (18.8)                                                           0.160
  Previous angina                                                                            48 (33.8)                                 20 (25.0)                                                           0.230
  Chronic renal failure                                                                    11 (7.7)                                    8 (10.0)                                                            0.620
  STEMI                                                                                    102 (71.8)                                  60 (75.0)                                                           0.640
  LVEF (%)                                                                                 51.9±9.0                                  51.9±6.7                                                              0.950
  Killip class                                                                                                                                                                                             0.003
    II                                                                                       95 (66.9)                                 40 (50.0)                                                         --
    III                                                                                      26 (18.3)                                 13 (16.25)                                                        --
    IV                                                                                       17 (11.9)                                 26 (32.5)                                                         --
  Heart beats (beats/min)                                                                  85.9±22.0                                 84.9±26.9                                                             0.750
  Arrhythmia                                                                                 20 (14.1)                               10 (12.5                                                              0.790
    AF                                                                                       16 (16.3)                                 7 (8.75)                                                          
    VA                                                                                       4 (2.8)                                   3 (3.75)                                                          
  Serum creatinine^[a](#tfn7-etm-0-0-3211){ref-type="table-fn"}^ (µmol/l) median (range)   88.0 (7.0, 732.0)                         98.0 (39.0, 860.0)                                                    0.020
  Urea nitrogen (mmol/l)                                                                   8.23±4.94                                 9.02±4.71                                                             0.250
  CKMB^[a](#tfn7-etm-0-0-3211){ref-type="table-fn"}^ (ng/ml) median (range)                19.50 (0.2, 493.1)                        28.90 (0.1, 500.0)                                                    0.059
  PCI                                                                                        68 (47.9)                                 28 (35.0)                                                           0.070
  In-hospital cardiogenic shock                                                              21 (14.8)                                 28 (35.0)                                                           0.001
  In-hospital mortality                                                                      8 (5.6)                                   26 (32.5)                                                         \<0.001

Figures in parentheses are percentages.

Serum creatinine and CKMB values were obtained using a Mann-Whitney U-test. AF, atrial fibrillation; AMI, acute myocardial infarction; ACEI, angiotensin-converting enzyme inhibitor; BB, β-blockers; CKMB, creatine kinase MB; COPD, chronic obstructive pulmonary disease; HF, heart failure; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; VA, ventricular arrhythmia.

###### 

Clinical outcomes of the study population.

                           STEMI                   NSTEMI                                           
  ------------------------ ----------- ----------- --------- -------------------------- ----------- ---------
  In-hospital mortality    25 (15.4)     8 (3.2)   \<0.001     9 (15.0)                 1 (0.8)     \<0.001
  Atrial fibrillation      20 (12.3)     9 (3.6)     0.001     8 (13.3)                 3 (2.5)       0.007
  Major bleeding           4 (2.5)       1 (0.4)     0.080   0                          0           --
  Ventricular arrhythmia   28 (17.3)   14 (5.6)    \<0.001     7 (11.7)                 9 (7.6)       0.410
  Recurrent ischemia       17 (10.5)   17 (6.8)      0.200     7 (11.7)                 9 (7.6)       0.410
  Re-MI                    2 (1.2)       4 (1.6)     1.000     2 (3.3)                  2 (1.7)       1.000
  Cardiogenic shock        40 (24.7)   0           --          9 (15.0)                 0           --
  High-grade AVB           4 (2.5)       7 (2.8)     1.000     2 (3.3)                  4 (3.4)       1.000
  MACEs                    82 (50.6)   41 (16.4)   \<0.001   21 ([@b35-etm-0-0-3211])   21 (17.6)     0.015
  Hospital stay (days)     12.8±9.7    9.4±5.3     \<0.001   13.9±9.2                   9.2±4.9     \<0.001

Figures in parentheses are percentages. High AVB including second- and third-degree heart blockage. MACEs included atrial fibrillation, ventricular arrhythmia, major bleeding, cardiogenic shock, recurrent ischemia, and Re-MI. AVB, atrioventricular blockage; HF, heart failure; MACEs, major cardiovascular events; NSTEMI, non-ST-segment elevation myocardial infarction; Re-MI, recurrent myocardial infarction; STEMI, ST-segment elevation myocardial infarction.

###### 

Predictors of in-hospital mortality.

  Variable                Adjusted OR   95% CI          P-value
  ----------------------- ------------- --------------- ---------
  Post-AMI HF             2.88          1.00, 8.28      0.049
  Cardiogenic shock       8.21            2.75, 24.48   0.000
  Age                     1.07          1.02, 1.12      0.006
  COPD                    0.05          0.00, 0.67      0.023
  Hospitalization days    0.93          0.87, 0.99      0.034
  Antiarrhythmic agents   4.59            1.84, 11.51   0.001
  β-blockers              0.43          0.61, 0.92      0.045
  ACEIs                   0.41          0.49, 0.87      0.041
  Co-prescriptions        0.24          0.16, 0.37      0.000
  Cardiac angiography     0.12          0.04, 0.35      0.000
  CKMB                    1.00          1.00, 1.01      0.038

ACEIs, angiotensin-converting enzyme inhibitors; AMI, acute myocardial infarction; CI, confidence interval; CKMB, creatine kinase MB; COPD, chronic obstructive pulmonary disease; Co-prescription, co-prescription of β-blockers and ACEIs; HF, heart failure; OR, odds ratio.

###### 

Comparison of all AMI patients stratified according to COPD status.

  Variable                                              COPD (n=50, 8.5%)        Non-COPD (n=541, 91.5%)   P-value
  ----------------------------------------------------- ------------------------ ------------------------- ---------
  HF                                                    31 (62.0)                191 (35.3)                \<0.001
  Men                                                   28 (56.0)                287 (53.0)                0.770
  Age                                                   74.2±8.1                   65.7±11.9               \<0.001
  Heart beats/min                                         81.4±23.7                79.6±19.8               0.540
  Serum creatinine (µmol/l)                             106.4±75.4                 93.7±63.6               0.190
  Urea nitrogen (mmol/l)                                  8.7±6.1                  7.3±5.9                 0.090
  CKMB^[a](#tfn10-etm-0-0-3211){ref-type="table-fn"}^   11.2 (1.5, 489.8)        18.7 (0.1, 515.0)         0.260
  LVEF                                                  52.8±9.7                 54.8±7.5                  0.080
  Hospital stay (days)                                  10.7±6.8                 10.8±7.4                  0.890
  STEMI                                                 31 (62.0)                381 (70.4)                0.260
  ACEI                                                  36 (72.0)                403 (74.5)                0.740
  β-blocker                                             32 (64.0)                448 (82.8)                0.002
  CCB                                                   13 (26.0)                135 (24.9)                0.870
  Diuretics                                             29 (58.0)                202 (37.3)                0.006
  Digitalis                                             10 (20.0)                48 (8.7)                  0.020
  Clopidogrel                                           48 (96.0)                526 (97.2)                0.650
  Aspirin                                               45 (90.0)                489 (90.4)                0.810
  Thrombolytic therapy                                  1 ([@b2-etm-0-0-3211])     55 (10.2)               0.070
  PCI                                                   19 (38.0)                309 (57.1)                0.010
  Three-vessel disease                                    9 (18.0)               176 (32.5)                0.070
  TIMI flow grade at PCI 2--3                           18 (36.0)                307 (56.7)                0.160
  In-hospital cardiogenic shock                         4 (8.0)                  45 (8.3)                  1.000

Determined using the Mann-Whitney U-test. Figures in parentheses are percentages and continuous variables are means ± standard deviation. ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; CCB, calcium channel blockers; CKMB, creatine kinase MB; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
